Humacyte's (HUMA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a research report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

A number of other research analysts also recently weighed in on HUMA. Benchmark cut their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen lowered Humacyte from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Finally, HC Wainwright began coverage on Humacyte in a research report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $11.71.

Humacyte Stock Down 2.2%

HUMA stock traded down $0.06 during mid-day trading on Wednesday, hitting $2.67. The stock had a trading volume of 4,046,791 shares, compared to its average volume of 3,850,631. The stock has a market capitalization of $414.17 million, a price-to-earnings ratio of -3.87 and a beta of 1.89. The company has a current ratio of 3.68, a quick ratio of 3.28 and a debt-to-equity ratio of 0.36. Humacyte has a 1-year low of $1.15 and a 1-year high of $9.79. The company has a fifty day moving average of $2.42 and a 200 day moving average of $2.72.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.46 million. On average, equities analysts expect that Humacyte will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of HUMA. Beacon Pointe Advisors LLC grew its position in shares of Humacyte by 33.3% in the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company's stock valued at $101,000 after purchasing an additional 5,000 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in Humacyte by 25.3% during the 4th quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company's stock valued at $132,000 after purchasing an additional 5,293 shares during the period. Wealth Effects LLC grew its holdings in Humacyte by 5.8% in the 2nd quarter. Wealth Effects LLC now owns 102,167 shares of the company's stock valued at $214,000 after buying an additional 5,600 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Humacyte by 20.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company's stock worth $172,000 after buying an additional 5,801 shares during the period. Finally, MetLife Investment Management LLC increased its position in Humacyte by 14.4% in the 1st quarter. MetLife Investment Management LLC now owns 51,442 shares of the company's stock worth $88,000 after buying an additional 6,482 shares during the period. Institutional investors and hedge funds own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.